National Institute on Aging; Notice of Closed Meeting, 9581 [08-774]
Download as PDF
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Regulation of Adaptive
Immunity by the Innate Immune System.
Date: March 13, 2008.
Time: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, MSC 3136, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Mercy R. Prabhudas, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
451–2615, mp457n@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–773 Filed 2–20–08; 8:45 am]
National Institutes of Health
pwalker on PROD1PC71 with NOTICES
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
Jkt 214001
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–774 Filed 2–20–08: 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Development and
Commercialization of Therapeutic
Products for Breast Cancer
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
16:34 Feb 20, 2008
Name of Committee: National Institute on
Aging Special Emphasis Panel; SWAN.
Date: March 4, 2008.
Time: 2 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20814 (Telephone Conference Call).
Contact Person: Alicja L. Markowska, PhD,
DSC, National Institute on Aging, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–496–9666,
markowsa@nia.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
AGENCY:
BILLING CODE: 4140–01–M
VerDate Aug<31>2005
would constitute a clearly unwarranted
invasion of personal privacy.
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), announces that the
Department of Health and Human
Services is contemplating the grant of an
exclusive license to practice the
inventions embodied in U.S. Patent
Application No. 09/693,600 filed
October 20, 2000 entitled ‘‘Method and
Composition for Enhancing Immune
Response’’ [E–037–2001/1–US–01];
Japanese Patent Application No. 2002–
555834 filed October 22, 2001 entitled
‘‘Method and Composition for
Enhancing Immune Response’’ [E–037–
2001/1–JP–03]; and European Patent
Application No. 01989341.1 filed
October 22, 2001 entitled ‘‘Method and
Composition for Enhancing Immune
Response’’ [E–037–2001/1–EP–04]; to
ODC Therapy, Inc.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to
therapeutic applications for breast
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
9581
cancer patients expressing high levels of
serum or plasma IgE.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before April 21, 2008 will be
considered.
ADDRESSES: Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: Mojdeh
Bahar, J.D., M.A., Technology Licensing
Specialist, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD. 20852–3804. Telephone:
(301) 435–2950; Facsimile: (301) 402–
0220; E-mail: baharm@od.nih.gov.
SUPPLEMENTARY INFORMATION: The
invention relates to a method of
inhibiting tumor growth which
comprises the administration of an IL–
13 inhibitor. Additionally, the invention
relates to a method and composition for
enhancing an immune response in a
subject by administering to a subject an
inhibitor of IL–13 or an inhibitor of an
NK–T cell. The method can be used to
prevent growth of a tumor in a subject,
e.g., to inhibit tumor recurrence or
metastasis. The method can also be used
to enhance a response to a vaccine in a
subject. IL–13 is an interleukin which
has potent immunomodulatory effects.
It is primarily secreted by TH2
lymphocytes. This invention relates to
the discovery of a role for IL–13 in the
down-regulation of tumor
immunosurveillance. Using a mouse
model in which tumors show a growthregression-recurrence pattern, the
mechanisms for down-regulation of
cytotoxic T lymphocyte-mediated tumor
immunosurveillance was investigated. It
was discovered that interleukin 4
receptor (IL–4R) knockout mice, and
downstream signal transducer and
activator of transcription 6 (STAT6)
knockout mice, but not IL–4 knockout
mice, resisted tumor recurrence. Thus,
IL–13, the only other cytokine that uses
the IL–4R–STAT6 pathway, was
discovered to have a role in the downregulation of tumor
immunosurveillance.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
E:\FR\FM\21FEN1.SGM
21FEN1
Agencies
[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Page 9581]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 08-774]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; SWAN.
Date: March 4, 2008.
Time: 2 p.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, 7201 Wisconsin Avenue, Suite
2C212, Bethesda, MD 20814 (Telephone Conference Call).
Contact Person: Alicja L. Markowska, PhD, DSC, National
Institute on Aging, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD
20892, 301-496-9666, markowsa@nia.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-774 Filed 2-20-08: 8:45 am]
BILLING CODE 4140-01-M